Our company provides technological and analytical background for clinical registries of the Czech Society for Oncology, which have been established for the monitoring of effectiveness and safety of targeted cancer therapy. Similarly to previous years, data analyses of these registries were used as a background for a series of articles published in international medical journals.
Considering the impact factor value, the most interesting outcome is undoubtedly the RENIS registry-based paper entitled Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis, published in European Urology (IF 16,265).
The higher number of outputs, however, arose from the TULUNG registry (6 articles), 2 papers were based on the RENIS registry and other 2 papers on the CORECT registry.
CORECT registry:
- Kiss I, Mlčochová J, Bortlíček Z, Poprach A, Drábek J, Vychytilová P, Svoboda M, Büchler T, Batko S, Ryška A, Hajdúch M, Slabý O. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients. Anticancer Research 2016; 36(9): 4955-4959.
- Fiala O, Buchler T, Mohelnikova-Duchonova B, Melichar B, Matejka VM, Holubec L, Kulhankova J, Bortlicek Z, Bartouskova M, Liska V, Topolcan O, Sedivcova M, Finek J. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumor Biology 2016; 37(5): 6823-6830.
RENIS registry:
- Büchler T, Bortlíček Z, Poprach A, Pavlík T, Veškrnová V, Honzírková M, Zemanová M, Fiala O, Kubáčková K, Slabý O, Svoboda M, Vyzula R, Dušek L, Melichar B. Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis. European Urology 2016; 70(3): 469-475.
- Poprach A, Lakomý R, Bortlíček Z, Melichar B, Pavlík T, Slabý O, Vyzula R, Svoboda M, Kiss I, Študentová H, Zemanová M, Fiala O, Kubáčková K, Dušek L, Hornová J, Büchler T. Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. Drugs & Aging 2016; 33(9): 655-663.
TULUNG registry:
- Fiala O, Pesek M, Finek J, Racek J, Minarik M, Benesova L, Bortlicek Z, Sorejs O, Kucera R, Topolcan O. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib. Neoplasma 2016; 63(3): 471-476.
- Fiala O, Pesek M, Finek J, Svaton M, Minarik M, Benesova L, Bortlicek Z, Kucera R., Topolcan O. Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene. Anticancer Research 2016; 36(1): 447-453.
- Fiala O, Pesek M, Finek J, Svaton M, Sorejs O, Bortlicek Z, Kucera R, Topolcan O. Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy. Anticancer Research 2016; 36(1): 461-466.
- Fiala O, Pesek M, Finek J, Minarik M, Benesova L, Sorejs O, Svaton M, Bortlicek Z, Kucera R, Topolcan O. Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC. Anticancer Research 2016; 36(1): 455-460.
- Fiala O, Pesek M, Finek J, Topolčan O, Racek J, Svaton M, Kucera R, Minarik M, Benesova, L, Bortlicek Z, Chloupkova R, Poprach A, Buchler T. Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib. Anticancer Research 2016; 36(5): 2459-2465.
- Svaton M, Fiala O, Pesek M, Bortlicek Z, Minarik M, Benesova L, Topolcan O. The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy. Anticancer Research 2016; 36(3): 1077-1082.
4. 5. 2017
Back
